Cancer Family
Digestive System Neoplasm
CI-CAN-00000012Explore in graph →
Non-malignant4,732 active trials43 approved drugs557 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000012Explore in graph →
Clinical trials
22,051 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03867370 | Toripalimab in Combination With Lenvatinib as Neoadjuvant Therapy in Resectable Hepatocellular Carcinoma | terminated | Phase 1 / Phase 2 | 40 | Shanghai Junshi Bioscience Co., Ltd.OTHER | 1 | Nov 29, 2023 | clinicaltrials |
| NCT04637698 | OH2 Oncolytic Viral Therapy in Pancreatic Cancer | terminated | Phase 1 / Phase 2 | 5 | Binhui Biopharmaceutical Co., Ltd.INDUSTRY | 1 | Nov 24, 2023 | clinicaltrials |
| NCT03649321 | Clinical Trial of Chemotherapy and Bemcentinib for Metastatic Pancreatic Cancer | terminated | Phase 1 / Phase 2 | 9 | University of Texas Southwestern Medical CenterOTHER | 1 | Nov 9, 2023 | clinicaltrials |
| NCT01133990 | FOLFIRI Alone Versus FOLFIRI Plus Bevacizumab Versus FOLFIRI Plus E7820 as Second-Line Therapy in Patients With Locally Advanced or Metastatic Colorectal Cancer | terminated | Phase 1 / Phase 2 | 5 | Eisai Inc.INDUSTRY | 5 | Nov 7, 2023 | clinicaltrials |
| NCT03555149 | A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic Colorectal Cancer (Morpheus-CRC) | terminated | Phase 1 / Phase 2 | 96 | Hoffmann-La RocheINDUSTRY | 5 | Nov 7, 2023 | clinicaltrials |
| NCT04983407 | Safety and Efficacy Study of AVB-S6-500 (Batiraxcept) in Patients With Advanced Pancreatic Adenocarcinoma | terminated | Phase 1 / Phase 2 | 34 | Aravive, Inc.INDUSTRY | 1 | Oct 30, 2023 | clinicaltrials |
| NCT01545141 | Chemokine-Modulatory Regimen for Recurrent Resectable Colorectal Cancer | terminated | Phase 1 / Phase 2 | 15 | Roswell Park Cancer InstituteOTHER | 1 | Oct 27, 2023 | clinicaltrials |
| NCT03722108 | Regorafenib Combined With Irinotecan as Second-line in Patients With Metastatic Gastro-oesophageal Adenocarcinomas(REGIRI) | terminated | Phase 1 / Phase 2 | 89 | UNICANCEROTHER | 1 | Oct 16, 2023 | clinicaltrials |
| NCT03122106 | Neoantigen DNA Vaccine in Pancreatic Cancer Patients Following Surgical Resection and Adjuvant Chemotherapy | terminated | Phase 1 | 15 | Washington University School of MedicineOTHER | 1 | Oct 10, 2023 | clinicaltrials |
| NCT00006046 | Monoclonal Antibody Therapy in Treating Patients With Advanced Colorectal Cancer | terminated | Phase 1 | 7 | Ludwig Institute for Cancer ResearchOTHER | 1 | Oct 4, 2023 | clinicaltrials |
| NCT05395052 | FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors | terminated | Phase 1 | 5 | Fate TherapeuticsINDUSTRY | 1 | Sep 21, 2023 | clinicaltrials |
| NCT03576131 | GEN1029 (HexaBody®-DR5/DR5) Safety Trial in Patients With Malignant Solid Tumors | terminated | Phase 1 / Phase 2 | 48 | GenmabINDUSTRY | 3 | Aug 1, 2023 | clinicaltrials |
| NCT04424641 | A Study on the Safety of GEN1044 (DuoBody®-CD3x5T4) in Patients With Malignant Solid Tumors | terminated | Phase 1 / Phase 2 | 48 | GenmabINDUSTRY | 4 | Jul 25, 2023 | clinicaltrials |
| NCT00677924 | Zalutumumab With or Without Irinotecan Chemotherapy in Cetuximab-Refractory Colorectal Cancer(GEN206) | terminated | Phase 1 / Phase 2 | 9 | GenmabINDUSTRY | 1 | Jul 18, 2023 | clinicaltrials |
| NCT00788125 | Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors | terminated | Phase 1 / Phase 2 | 7 | City of Hope Medical CenterOTHER | 1 | Jul 14, 2023 | clinicaltrials |
| NCT03970616 | A Study of Tivozanib in Combination With Durvalumab in Subjects With Advanced Hepatocellular Carcinoma(DEDUCTIVE) | terminated | Phase 1 / Phase 2 | 27 | AVEO Pharmaceuticals, Inc.INDUSTRY | 1 | Jul 12, 2023 | clinicaltrials |
| NCT02530437 | Taladegib, Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Localized Esophageal or Gastroesophageal Junction Cancer | terminated | Phase 1 / Phase 2 | 7 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 10, 2023 | clinicaltrials |
| NCT03724071 | Study of TG6002 (VV TK-RR-FCU1) in Combination With 5-FC in Patients With Advanced Gastro-intestinal Tumors. | terminated | Phase 1 / Phase 2 | 51 | TransgeneINDUSTRY | 3 | Jun 23, 2023 | clinicaltrials |
| NCT04194034 | Study of Intrahepatic Arterial Infusion of TG6002 in Combination With 5-FC in Patients With Metastatic Colorectal Cancer | terminated | Phase 1 / Phase 2 | 15 | TransgeneINDUSTRY | 2 | Jun 23, 2023 | clinicaltrials |
| NCT01347645 | Irinotecan Plus E7820 Versus FOLFIRI in Second-Line Therapy in Patients With Locally Advanced or Metastatic Colon or Rectal Cancer | terminated | Phase 1 / Phase 2 | 82 | Eisai Inc.INDUSTRY | 6 | Jun 22, 2023 | clinicaltrials |
| NCT02489201 | A Study of Donafenib Monotherapy in Advanced Oesophageal Cancer | terminated | Phase 1 / Phase 2 | 19 | Suzhou Zelgen Biopharmaceuticals Co.,LtdINDUSTRY | 1 | Jun 15, 2023 | clinicaltrials |
| NCT04193904 | A Study of Live Biotherapeutic Product MRx0518 With Hypofractionated Radiation Therapy in Resectable Pancreatic Cancer | terminated | Phase 1 | 13 | 4D pharma plcINDUSTRY | 1 | Jun 2, 2023 | clinicaltrials |
| NCT05375604 | A Study of exoASO-STAT6 (CDK-004) in Patients With Advanced Hepatocellular Carcinoma (HCC) and Patients With Liver Metastases From EIther Primary Gastric Cancer or Colorectal Cancer (CRC) | terminated | Phase 1 | 9 | Codiak BioSciencesINDUSTRY | 1 | Jun 1, 2023 | clinicaltrials |
| NCT03233724 | Oral Decitabine and Tetrahydrouridine as Epigenetic Priming for Pembrolizumab-Mediated Immune Checkpoint Blockade in Patients With Inoperable, or Unresectable Locally Advanced or Metastatic Non-Small Cell Lung Cancers and Esophageal Carcinomas | terminated | Phase 1 / Phase 2 | 9 | National Cancer Institute (NCI)NIH | 1 | May 31, 2023 | clinicaltrials |
| NCT02961283 | Study of ASN003 in Subjects With Advanced Solid Tumors | terminated | Phase 1 | 24 | Asana BioSciencesINDUSTRY | 1 | May 9, 2023 | clinicaltrials |
| NCT02489214 | Donafenib Monotherapy for Previously Treated Metastatic Gastric Cancer | terminated | Phase 1 / Phase 2 | 13 | Suzhou Zelgen Biopharmaceuticals Co.,LtdINDUSTRY | 1 | May 8, 2023 | clinicaltrials |
| NCT02376699 | Safety Study of SEA-CD40 in Cancer Patients | terminated | Phase 1 | 159 | Seagen Inc.INDUSTRY | 1 | May 1, 2023 | clinicaltrials |
| NCT01160926 | Dual REctcal Angiogenesis or MEK Inhibition radioTHERAPY Trial(DREAMtherapy) | terminated | Phase 1 | 31 | The Christie NHS Foundation TrustOTHER | 1 | Apr 24, 2023 | clinicaltrials |
| NCT03118349 | Study of 177Lu Human Monoclonal Antibody 5B1 (MVT-1075) in Combination With a Blocking Dose of MVT-5873 as Radioimmunotherapy | terminated | Phase 1 | 4 | BioNTech Research & Development, Inc.INDUSTRY | 1 | Apr 21, 2023 | clinicaltrials |
| NCT04696848 | The Efficacy and Safety of CKD516 Combined With Durvalumab in Patient Refractory Solid Tumors | terminated | Phase 1 / Phase 2 | 25 | Tae Won KimOTHER | 1 | Apr 21, 2023 | clinicaltrials |
| NCT04042480 | A Study of SGN-CD228A in Advanced Solid Tumors | terminated | Phase 1 | 88 | Seagen Inc.INDUSTRY | 5 | Mar 23, 2023 | clinicaltrials |
| NCT04635527 | A Study on the Safety and Effectiveness of IBI318 Combined With Conventional TACE (cTACE) as a Perioperative Treatment for Potentially Resected Hepatocellular Carcinoma | terminated | Phase 1 | 10 | Innovent Biologics (Suzhou) Co. Ltd.INDUSTRY | 1 | Mar 16, 2023 | clinicaltrials |
| NCT03435640 | REVEAL Study of NKTR-262 in Combination With NKTR-214 and Nivolumab in Patients With Locally Advanced / Metastatic Solid Tumor Malignancies(REVEAL) | terminated | Phase 1 / Phase 2 | 64 | Nektar TherapeuticsINDUSTRY | 1 | Mar 8, 2023 | clinicaltrials |
| NCT01239095 | Oral Green Tea Extract and Milk Thistle Extract to Colorectal Cancer Patients Undergoing Resection | terminated | Phase 1 | 23 | Richard WhelanOTHER | 1 | Feb 22, 2023 | clinicaltrials |
| NCT04177602 | Evaluating Trifluridine/Tipiracil Based Chemoradiation in Locally Advanced Rectal Cancer - The Phase I/II TARC Trial | terminated | Phase 1 / Phase 2 | 10 | Universitätsklinikum Hamburg-EppendorfOTHER | 1 | Feb 22, 2023 | clinicaltrials |
| NCT03791398 | BrUOG 379 Phase Ib/II Trial ONC201 + Nivolumab in MSS mCRC(379) | terminated | Phase 1 / Phase 2 | 13 | Brown UniversityOTHER | 1 | Feb 17, 2023 | clinicaltrials |
| NCT03818165 | Phase 1b Study of CAR2Anti-CEA CAR-T Cell Hepatic Infusions for Pancreatic Carcinoma Patients With CEA+ Liver Metastases(AntiCEA_CART) | terminated | Phase 1 | 2 | Sorrento Therapeutics, Inc.INDUSTRY | 1 | Jan 17, 2023 | clinicaltrials |
| NCT01952730 | Pilot Study of GVAX in Colorectal Cancer Cells | terminated | Phase 1 | 1 | Massachusetts General HospitalOTHER | 1 | Jan 12, 2023 | clinicaltrials |
| NCT02910843 | Neoadjuvant Treatment With Regorafenib and Capecitabine Combined With Radiotherapy in Locally Advanced Rectal Cancer(RECAP) | terminated | Phase 1 | 25 | Swiss Cancer InstituteOTHER | 1 | Jan 10, 2023 | clinicaltrials |
| NCT04044430 | Encorafenib, Binimetinib, and Nivolumab in Treating Microsatellite Stable BRAF V600E Metastatic Colorectal Cancer | terminated | Phase 1 | 2 | University of California, San FranciscoOTHER | 1 | Jan 9, 2023 | clinicaltrials |
| NCT02393248 | Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101) | terminated | Phase 1 / Phase 2 | 201 | Incyte CorporationINDUSTRY | 2 | Jan 6, 2023 | clinicaltrials |
| NCT04672980 | RTX-321 Monotherapy in Patients With HPV 16+ Tumors | terminated | Phase 1 | 9 | Rubius TherapeuticsINDUSTRY | 1 | Dec 8, 2022 | clinicaltrials |
| NCT04304781 | Phase 1 In-vivo Biliary Study of KSP/QRH Heptapeptide Dimer | terminated | Phase 1 | 12 | Danielle Kim TurgeonOTHER | 1 | Nov 22, 2022 | clinicaltrials |
| NCT02437916 | Safety Study of AMG 228 to Treat Solid Tumors | terminated | Phase 1 | 30 | AmgenINDUSTRY | 5 | Nov 8, 2022 | clinicaltrials |
| NCT05093608 | SELINEXOR in Combination w/Bevacizumab and Atezolizumab in Newly Diagnosed Advanced Hepatocellular Carcinoma | terminated | Phase 1 | 2 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Oct 17, 2022 | clinicaltrials |
| NCT03945799 | A Multicenter Study of Anlotinib in Hepatocellular Carcinoma (HCC) Patients at High Risk of Post Surgery Recurrence | terminated | Phase 1 / Phase 2 | 28 | Zhejiang UniversityOTHER | 1 | Aug 31, 2022 | clinicaltrials |
| NCT03998033 | Study of ET140202 T Cells in Adults With Advanced Hepatocellular Carcinoma(ET-109) | terminated | Phase 1 | 2 | Eureka Therapeutics Inc.INDUSTRY | 1 | Aug 23, 2022 | clinicaltrials |
| NCT04060342 | GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma | terminated | Phase 1 | 61 | GB006, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.INDUSTRY | 2 | Aug 18, 2022 | clinicaltrials |
| NCT05091528 | A Safety and Activity Study of SBT6050 in Combination With Other HER2-directed Therapies for HER2-positive Cancers | terminated | Phase 1 / Phase 2 | 2 | Silverback TherapeuticsINDUSTRY | 1 | Aug 18, 2022 | clinicaltrials |
Data updated 22 days agoSource updated Nov 29, 2023source: clinicaltrials